Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

University of Wisconsin (UW)

Status and phase

Enrolling

Phase 1

Conditions

Somatostatin Receptor-positive Neuroendocrine Tumor

Neuroendocrine Tumors

Treatments

Device: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)

Drug: 64Cu-Dotatate

Device: Photon Emission Tomography / CT (PET/CT)

Drug: 177Lu-Dotatate

Study type

Interventional

Funder types

Other

Identifiers

NCT06122610

Protocol Version 12/12/2025 (Other Identifier)

2023-0121

SMPH/RADIOLOGY/RADIOLOGY (Other Identifier)

Details and patient eligibility

About

The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer.

Participants will:

Complete two phases involving 6 visits
Undergo additional research PET/CT, and possibly SPECT/CT scans

Full description

The goal of this research study is to determine if DetectnetTM PET/CT scanning over several days can be used to deliver Lutathera in a safer manner.

In this research, participants will be asked to complete a screening phase and possibly a dosimetry phase. The screening phase will require 2 visits. The dosimetry phase will also require 3 research visits.

Enrollment

10 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor

Exclusion criteria

Unable to lie flat during or tolerate PET/CT or SPECT/CT
Known incompatibility to CT. SPECT, or PET scans
Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study